GERN
Geron
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
GERN Profile
Geron Corporation
A late-stage clinical biopharmaceutical company that develops telomerase-targeted and peptide-drug conjugate therapies for cancers
919 East Hillsdale Boulevard
, Suite 250
, Foster City
, CA 94404
--
Geron Corporation was incorporated in Delaware on November 28, 1990. The company is a biopharmaceutical company that develops first-in-class treatments for cancer treatment. Imetelstat is a novel, first-in-class telomerase inhibitor and a candidate for the company's clinically developing product. Telomerase enables tumor cells to maintain telomere length, which provides the ability for infinite cellular replication. Imetelstat is a potent specific telomerase inhibitor. On the basis of clinical data obtained at the end of 2012, Imetelstat may be developed for the treatment of one or more myeloid malignancies of the hematopoietic system, such as myelofibrosis, or MF, myelodysplastic syndrome, or acute myeloid leukemia. Using the company's proprietary nucleic acid chemistry, Imetelstat is designed to modify oligonucleotides, the active site of telomerase has a high affinity, thereby directly inhibiting telomerase activity. The company's development of Imetelstat and US commercial patent coverage extends to 2025.